
    
      Subjects who completed the 24-week assessment period and achieved at least 20% improvement in
      swollen joint count (SJC) and/or tender joint count (TJC) at Week 24 of study ALX0061-C201
      were invited to participate in an open-label extension (OLE) study ALX0061-C203
      (NCT02518620), if the study was approved in their country and selection criteria were met.
    
  